Business Context and Reporting Period
Company: Alaunos Therapeutics, Inc. (TCRT)
Filing Type: Form 8-K (Current Report)
Date of Report: April 7, 2025 (Event Date)
Reporting Period: The filing addresses events occurring on April 7, 2025, and April 9, 2025, referencing financial data from the Annual Report on Form 10-K for the period ended December 31, 2024.
Key Financial Metrics
Stockholders' Equity: $2,063,000 (as reported in the 2024 10-K).
Nasdaq Minimum Requirement: $2,500,000 (Rule 5550(b)(1)).
Revenue, Profit, Cash Flow, Debt: The filing text does not provide specific values for revenue, profit, cash flow, margins, or debt levels beyond the stockholders' equity figure.
Material Changes and Listing Status
- Delisting Notice: On April 7, 2025, the Company received notice from Nasdaq that its stockholders' equity of $2,063,000 failed to meet the minimum requirement of $2,500,000 for continued listing on the Nasdaq Capital Market.
- Immediate Effect: The notice has no immediate effect on the Company's listing status.
- Compliance Timeline: The Company has 45 calendar days from April 7, 2025, to submit a plan to regain compliance. If accepted, the Company may be granted up to 180 calendar days to evidence compliance.
- Monitor Status Update: On April 9, 2025, the Company received confirmation that it is no longer subject to a one-year Panel Monitor, concluding the requirement outlined in a February 16, 2024 letter.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to submit a compliance plan within the 45-day window and will evaluate available options to resolve the equity deficiency.
Risks: Failure to regain compliance with Nasdaq Listing Rule 5550(b)(1) could result in delisting from the Nasdaq Capital Market.
Unusual Items: None reported beyond the equity deficiency and the conclusion of the Panel Monitor status.
Investor Verification Checklist
- Verify the Company's submission of a compliance plan to Nasdaq within 45 days of April 7, 2025.
- Monitor the acceptance of the compliance plan and the subsequent 180-day timeline for regaining equity compliance.
- Review the 2024 Form 10-K to understand the full financial context of the $2,063,000 stockholders' equity figure.
- Confirm the Company's ongoing operational status and capital raise activities intended to address the equity shortfall.